Abstract
Human immunodeficiency virus (HIV) damages the bodys immune system making secondary (or opportunistic) infections more common. Treatment and prevention of such infections is integral to the management of patients with HIV infection. Co-trimoxazole is a prophylactic treatment that has a wide range of action against common bacteria parasites fungi and yeasts. As part of a minimum care package UNAIDS/ WHO recommends co-trimoxazole prophylaxis for HIV infected adults with symptomatic disease (WHO stage II III or IV) or asymptomatic individuals with CD4 counts <or=500 cells/il and for all HIV-positive pregnant women after the first trimester. Co-trimoxazole is also recommended for use in children with proven HIV infection and infants exposed to HIV (from 4 - 6 weeks of age until infection with HIV is ruled out). The object of this report is to summarise the effects of co-trimoxazole prophylaxis on morbidity and mortality among HIV-infected individuals.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
